TriSalus Life Sciences (NASDAQ:TLSI) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of TriSalus Life Sciences (NASDAQ:TLSI) from a hold rating to a sell rating in a research note issued to investors on Sunday morning.

TriSalus Life Sciences Price Performance

TriSalus Life Sciences stock opened at $4.70 on Friday. The firm has a 50-day moving average of $4.63 and a 200-day moving average of $5.08. TriSalus Life Sciences has a one year low of $3.42 and a one year high of $5.88. The company has a market cap of $234.39 million, a price-to-earnings ratio of -3.98 and a beta of 0.49.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05). The firm had revenue of $11.21 million for the quarter, compared to the consensus estimate of $10.69 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that TriSalus Life Sciences will post -1.55 earnings per share for the current year.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Bank of America Corp DE raised its holdings in shares of TriSalus Life Sciences by 1.8% in the 2nd quarter. Bank of America Corp DE now owns 188,906 shares of the company’s stock valued at $1,030,000 after purchasing an additional 3,374 shares during the period. Connective Capital Management LLC lifted its position in TriSalus Life Sciences by 12.8% during the second quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock worth $179,000 after acquiring an additional 3,717 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in TriSalus Life Sciences during the second quarter worth approximately $29,000. Northern Trust Corp lifted its position in TriSalus Life Sciences by 22.7% during the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock worth $161,000 after acquiring an additional 5,936 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after acquiring an additional 7,519 shares during the last quarter. 2.58% of the stock is owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.